UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007024
Receipt number R000008287
Scientific Title A open label, randomized, controled trial to assess the utility of Pitavastatin for patients with type2 diabetes and obesity in Matsuyama Shimin Hospital.
Date of disclosure of the study information 2012/01/06
Last modified on 2014/01/14 14:09:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A open label, randomized, controled trial to assess the utility of Pitavastatin for patients with type2 diabetes and obesity in Matsuyama Shimin Hospital.

Acronym

Utility of Pitavastatin for patients with type2 diabetes and obesity in Matsuyama Shimin Hospital(POM study).

Scientific Title

A open label, randomized, controled trial to assess the utility of Pitavastatin for patients with type2 diabetes and obesity in Matsuyama Shimin Hospital.

Scientific Title:Acronym

Utility of Pitavastatin for patients with type2 diabetes and obesity in Matsuyama Shimin Hospital(POM study).

Region

Japan


Condition

Condition

Type 2 diabetic patients with hyperlipidemia

Classification by specialty

Cardiology Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

It aims at examining the improvement action and the mechanism of blood sugar or lipid by switch from atrovastatin to pitavastatin.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

change about HbA1c

Key secondary outcomes

1)change in following laboratory data
1.fasting Glucose
2.HOMA-IR
3.adiponectin
4.hs-CRP
5.visceral fat,hepatic CT
6.AST,ALT
7.serum lipids (TC,LDL-C,HDL-C,TG)
8.Apoprotein (ApoA-1,ApoB,ApoE)

2) Relationship of following laboratory data
1. Relationship of change about HbA1c and change about each laboratory data
2. Relationship BMI and change about each laboratory data
3. Relationship of change about serum lipids(LDL-C,HDL-C,TG),Apoprotein(ApoA-1,ApoB,ApoE)and change about each laboratory data
4. Relationship of change about ALT,AST and change about each laboratory data
5. Relationship of change about visceral fat,hepatic CT and change about each laboratory data


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

YES

Institution consideration


Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

(Pitavastatin group)
Patients under treatment with pitavastatin (2mg/day) are switched from atrovastatin (10mg/day) to pitavastatin at the dose of 2mg/day for 6months.

Interventions/Control_2

(Atrovastatin group)
Patients under treatment with atrovastatin (10mg/day) group will continue therapy with atrovastatin at the dose of 10 mg/day for 6 months.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients who have been under treatment with atrovastatin for hyperlipidemia for more than 3 months.
2) Patients with type 2 diabetes mellitus.
3) Patients with HbA1c level 6.5-7.9%.
4) Patients with BMI level 25 or more.

Key exclusion criteria

1) Patients with insulin.
2) Patients requiring hospitalization to attain glycemic control.
3) Patients who have hypersensitivity to LIVALO tablet.
4) Patients who have severe liver dysfunction or biliary atresia.
5)Patients who are being treated with cyclosporine.
6) Pregnant women, women suspected of being pregnant, or lactating women.
7) Patients judged inadequate to participate in this study by their physician.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name TETSUJI NIIYA

Organization

MATSUYAMA SHIMIN HOSPITAL

Division name

Internal medicine

Zip code


Address

Ohtemachi 2-6-5, Matsuyama city, Ehime prefecture

TEL

089-943-1151

Email



Public contact

Name of contact person

1st name
Middle name
Last name TETSUJI NIIYA

Organization

MATSUYAMA SHIMIN HOSPITAL

Division name

Internal medicine

Zip code


Address

Ohtemachi 2-6-5, Matsuyama city, Ehime prefecture

TEL

089-943-1151

Homepage URL


Email

t.niiya@matsuyama-shimin-hsp.or.jp


Sponsor or person

Institute

MATSUYAMA SHIMIN HOSPITAL

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

松山市民病院(愛媛県)


Other administrative information

Date of disclosure of the study information

2012 Year 01 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2011 Year 09 Month 28 Day

Date of IRB


Anticipated trial start date

2012 Year 01 Month 01 Day

Last follow-up date

2014 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 01 Month 06 Day

Last modified on

2014 Year 01 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008287


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name